IQVIA Holdings Inc. (IQV) EV/EBITDA Ratio: 8.90x
Is IQVIA Holdings Inc.’s EV/EBITDA ratio high or low?
IQVIA Holdings Inc.'s EV/EBITDA ratio of 8.90x is 48% below its 5-year average of 17.09x, near the low end of its 5-year range (7.87x–26.79x).
The EV/EBITDA ratio for IQVIA Holdings Inc. (IQV) is 8.90x as of Wednesday, June 10, 2026. It is below its 12-month average by 32.52% (13.19x).
IQV EV/EBITDA Ratio Chart
IQV Average EV/EBITDA Ratio Chart
IQV Current vs Average EV/EBITDA Ratio Chart
IQV EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
8.90x
EV/EBITDA RATIO AVG TTM
13.19x
EV/EBITDA RATIO AVG 3Y
14.98x
EV/EBITDA RATIO AVG 5Y
17.09x
EV/EBITDA RATIO AVG 10Y
18.58x
EV/EBITDA RATIO AVG 15Y
17.46x
EV/EBITDA RATIO AVG 20Y
17.46x
CURRENT VS TTM AVG
-32.52%
CURRENT VS 3Y AVG
-40.57%
CURRENT VS 5Y AVG
-47.92%
CURRENT VS 10Y AVG
-52.10%
CURRENT VS 15Y AVG
-49.03%
CURRENT VS 20Y AVG
-49.03%
IQV Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | — | 8.90x | 13.19x | 14.98x | 17.09x |
| Centene Corporation (CNC) | $31.94B | N/A | 4.99x | 7.28x | 9.49x |
| DexCom, Inc. (DXCM) | $29.24B | 23.24x | 28.10x | 43.48x | 70.03x |
| Biogen Inc. (BIIB) | $29.00B | 11.60x | 8.56x | 11.16x | 12.22x |
| Veeva Systems Inc. (VEEV) | $27.37B | 26.02x | 43.41x | 56.96x | 62.43x |
| Zoetis Inc. (ZTS) | $34.20B | 10.33x | 15.67x | 20.68x | 23.76x |
| Waters Corporation (WAT) | $23.83B | 38.03x | 21.59x | 21.24x | 21.45x |
| Agilent Technologies, Inc. (A) | $38.26B | 21.51x | 21.11x | 21.69x | 23.12x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 20.28x | 23.56x | 23.88x | 26.50x |
| BioNTech SE (BNTX) | $21.81B | N/A | 51.40x | 19.63x | 20.05x |
EV/EBITDA vs. its own history
At 8.9, EV/EBITDA is cheaper than usual — richer than 1% of its 13-year range.
13-year low
7.9
median
17.1
13-year high
28.9
Understanding EV/EBITDA
Enterprise Value (EV) = Market Cap + Total Debt - Cash
EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization
EV/EBITDA is commonly used for comparing companies because:
- It accounts for debt levels (capital structure neutral)
- It removes effects of different depreciation policies
- It can be compared across countries with different tax rates
- It can remain available when net income is negative, if EBITDA is positive
IQVIA Holdings Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for IQVIA Holdings Inc. (IQV)?
- The EV/EBITDA ratio for IQV stock is 8.90x.
- Is IQVIA Holdings Inc.'s EV/EBITDA ratio high or low?
- IQVIA Holdings Inc.'s EV/EBITDA ratio of 8.90x is 48% below its 5-year average of 17.09x, near the low end of its 5-year range (7.87x–26.79x).
- What is the TTM average EV/EBITDA ratio for IQVIA Holdings Inc. (IQV)?
- The TTM average EV/EBITDA ratio for IQV stock is 13.19x.
- What is the 3Y average EV/EBITDA ratio for IQVIA Holdings Inc. (IQV)?
- The 3Y average EV/EBITDA ratio for IQV stock is 14.98x.
- What is the 5Y average EV/EBITDA ratio for IQVIA Holdings Inc. (IQV)?
- The 5Y average EV/EBITDA ratio for IQV stock is 17.09x.
- What is the 10Y average EV/EBITDA ratio for IQVIA Holdings Inc. (IQV)?
- The 10Y average EV/EBITDA ratio for IQV stock is 18.58x.
- What is the 15Y average EV/EBITDA ratio for IQVIA Holdings Inc. (IQV)?
- The 15Y average EV/EBITDA ratio for IQV stock is 17.46x.
- What is the 20Y average EV/EBITDA ratio for IQVIA Holdings Inc. (IQV)?
- The 20Y average EV/EBITDA ratio for IQV stock is 17.46x.
IQVIA Holdings Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-10 | 8.90x |
| 2026-06-09 | 9.04x |
| 2026-06-08 | 8.92x |
| 2026-06-05 | 8.90x |
| 2026-06-04 | 9.07x |
| 2026-06-03 | 8.84x |
| 2026-06-02 | 8.77x |
| 2026-06-01 | 9.07x |
| 2026-05-29 | 8.84x |
| 2026-05-28 | 8.79x |
| 2026-05-27 | 8.04x |
| 2026-05-26 | 7.87x |
| 2026-05-22 | 8.15x |
| 2026-05-21 | 8.16x |
| 2026-05-20 | 8.33x |
| 2026-05-19 | 8.41x |
| 2026-05-18 | 8.39x |
| 2026-05-15 | 8.21x |
| 2026-05-14 | 8.29x |
| 2026-05-13 | 8.37x |
| 2026-05-12 | 8.50x |
| 2026-05-11 | 8.43x |
| 2026-05-08 | 8.67x |
| 2026-05-07 | 8.67x |
| 2026-05-06 | 8.57x |
| 2026-05-05 | 8.56x |
| 2026-05-04 | 12.08x |
| 2026-05-01 | 11.93x |
| 2026-04-30 | 11.96x |
| 2026-04-29 | 11.87x |
| 2026-04-28 | 11.99x |
| 2026-04-27 | 12.23x |
| 2026-04-24 | 12.15x |
| 2026-04-23 | 12.07x |
| 2026-04-22 | 12.79x |
| 2026-04-21 | 12.82x |
| 2026-04-20 | 12.87x |
| 2026-04-17 | 12.85x |
| 2026-04-16 | 12.63x |
| 2026-04-15 | 12.94x |
| 2026-04-14 | 12.80x |
| 2026-04-13 | 12.63x |
| 2026-04-10 | 12.40x |
| 2026-04-09 | 12.48x |
| 2026-04-08 | 12.66x |
| 2026-04-07 | 12.56x |
| 2026-04-06 | 12.57x |
| 2026-04-02 | 12.70x |
| 2026-04-01 | 12.65x |
| 2026-03-31 | 12.56x |
| 2026-03-30 | 12.34x |
| 2026-03-27 | 12.23x |
| 2026-03-26 | 12.50x |
| 2026-03-25 | 12.32x |
| 2026-03-24 | 12.34x |
| 2026-03-23 | 12.38x |
| 2026-03-20 | 12.34x |
| 2026-03-19 | 12.36x |
| 2026-03-18 | 12.39x |
| 2026-03-17 | 12.46x |
| 2026-03-16 | 12.28x |
| 2026-03-13 | 12.27x |
| 2026-03-12 | 12.18x |
| 2026-03-11 | 12.61x |
| 2026-03-10 | 12.58x |
| 2026-03-09 | 12.96x |
| 2026-03-06 | 12.76x |
| 2026-03-05 | 12.96x |
| 2026-03-04 | 12.92x |
| 2026-03-03 | 12.73x |
| 2026-03-02 | 12.75x |
| 2026-02-27 | 12.97x |
| 2026-02-26 | 12.57x |
| 2026-02-25 | 12.13x |
| 2026-02-24 | 12.28x |
| 2026-02-23 | 12.15x |
| 2026-02-20 | 12.32x |
| 2026-02-19 | 12.50x |
| 2026-02-18 | 12.59x |
| 2026-02-17 | 12.26x |
| 2026-02-13 | 12.24x |
| 2026-02-12 | 12.33x |
| 2026-02-11 | 12.75x |
| 2026-02-10 | 13.01x |
| 2026-02-09 | 13.52x |
| 2026-02-06 | 13.27x |
| 2026-02-05 | 12.94x |
| 2026-02-04 | 14.02x |
| 2026-02-03 | 14.08x |
| 2026-02-02 | 15.45x |
| 2026-01-30 | 15.40x |
| 2026-01-29 | 15.67x |
| 2026-01-28 | 15.88x |
| 2026-01-27 | 15.94x |
| 2026-01-26 | 15.86x |
| 2026-01-23 | 15.66x |
| 2026-01-22 | 15.84x |
| 2026-01-21 | 15.96x |
| 2026-01-20 | 15.58x |
| 2026-01-16 | 15.77x |
| 2026-01-15 | 15.95x |
| 2026-01-14 | 15.96x |
| 2026-01-13 | 15.97x |
| 2026-01-12 | 15.93x |
| 2026-01-09 | 16.01x |
| 2026-01-08 | 16.05x |
| 2026-01-07 | 16.10x |
| 2026-01-06 | 15.92x |
| 2026-01-05 | 15.62x |
| 2026-01-02 | 15.16x |
| 2025-12-31 | 15.16x |
| 2025-12-30 | 15.28x |
| 2025-12-29 | 15.25x |
| 2025-12-26 | 15.24x |
| 2025-12-24 | 15.19x |
| 2025-12-23 | 15.15x |
| 2025-12-22 | 15.11x |
| 2025-12-19 | 14.93x |
| 2025-12-18 | 15.02x |
| 2025-12-17 | 14.96x |
| 2025-12-16 | 14.97x |
| 2025-12-15 | 15.07x |
| 2025-12-12 | 15.00x |
| 2025-12-11 | 15.19x |
| 2025-12-10 | 15.04x |
| 2025-12-09 | 14.79x |
| 2025-12-08 | 15.07x |
| 2025-12-05 | 15.18x |
| 2025-12-04 | 15.14x |
| 2025-12-03 | 15.25x |
| 2025-12-02 | 15.17x |
| 2025-12-01 | 15.31x |
| 2025-11-28 | 15.39x |
| 2025-11-26 | 15.48x |
| 2025-11-25 | 15.49x |
| 2025-11-24 | 15.30x |
| 2025-11-21 | 15.14x |
| 2025-11-20 | 14.75x |
| 2025-11-19 | 14.76x |
| 2025-11-18 | 14.75x |
| 2025-11-17 | 14.70x |
| 2025-11-14 | 14.92x |
| 2025-11-13 | 15.07x |
| 2025-11-12 | 14.93x |
| 2025-11-11 | 14.82x |
| 2025-11-10 | 14.54x |
| 2025-11-07 | 14.41x |
| 2025-11-06 | 14.43x |
| 2025-11-05 | 14.40x |
| 2025-11-04 | 14.44x |
| 2025-11-03 | 14.58x |
| 2025-10-31 | 14.71x |
| 2025-10-30 | 14.71x |
| 2025-10-29 | 14.78x |
| 2025-10-28 | 14.80x |
| 2025-10-27 | 15.32x |
| 2025-10-24 | 15.48x |
| 2025-10-23 | 15.45x |
| 2025-10-22 | 15.35x |
| 2025-10-21 | 15.39x |
| 2025-10-20 | 15.05x |
| 2025-10-17 | 14.66x |
| 2025-10-16 | 14.72x |
| 2025-10-15 | 14.58x |
| 2025-10-14 | 14.67x |
| 2025-10-13 | 14.62x |
| 2025-10-10 | 14.33x |
| 2025-10-09 | 14.58x |
| 2025-10-08 | 14.45x |
| 2025-10-07 | 14.47x |
| 2025-10-06 | 14.68x |
| 2025-10-03 | 14.77x |
| 2025-10-02 | 14.65x |
| 2025-10-01 | 14.62x |
| 2025-09-30 | 13.90x |
| 2025-09-29 | 13.43x |
| 2025-09-26 | 13.37x |
| 2025-09-25 | 13.22x |
| 2025-09-24 | 13.45x |
| 2025-09-23 | 13.72x |
| 2025-09-22 | 13.79x |
| 2025-09-19 | 13.76x |
| 2025-09-18 | 13.92x |
| 2025-09-17 | 13.73x |
| 2025-09-16 | 13.74x |
| 2025-09-15 | 13.70x |
| 2025-09-12 | 13.76x |
| 2025-09-11 | 13.94x |
| 2025-09-10 | 13.59x |
| 2025-09-09 | 13.89x |
| 2025-09-08 | 13.79x |
| 2025-09-05 | 13.79x |
| 2025-09-04 | 13.60x |
| 2025-09-03 | 13.63x |
| 2025-09-02 | 13.58x |
| 2025-08-29 | 13.95x |
| 2025-08-28 | 13.84x |
| 2025-08-27 | 13.84x |
| 2025-08-26 | 13.79x |
| 2025-08-25 | 13.80x |
| 2025-08-22 | 13.96x |
| 2025-08-21 | 13.67x |
| 2025-08-20 | 14.01x |
| 2025-08-19 | 14.03x |
| 2025-08-18 | 14.04x |
| 2025-08-15 | 13.96x |
| 2025-08-14 | 13.87x |
| 2025-08-13 | 13.92x |
| 2025-08-12 | 13.69x |
| 2025-08-11 | 13.39x |
| 2025-08-08 | 13.38x |
| 2025-08-07 | 13.33x |
| 2025-08-06 | 13.26x |
| 2025-08-05 | 13.59x |
| 2025-08-04 | 13.53x |
| 2025-08-01 | 13.51x |
| 2025-07-31 | 13.69x |
| 2025-07-30 | 13.98x |
| 2025-07-29 | 14.14x |
| 2025-07-28 | 14.31x |
| 2025-07-25 | 14.38x |
| 2025-07-24 | 14.46x |
| 2025-07-23 | 14.12x |
| 2025-07-22 | 13.77x |
| 2025-07-21 | 11.87x |
| 2025-07-18 | 11.96x |
| 2025-07-17 | 12.09x |
| 2025-07-16 | 11.85x |
| 2025-07-15 | 11.81x |
| 2025-07-14 | 11.93x |
| 2025-07-11 | 12.07x |
| 2025-07-10 | 12.21x |
| 2025-07-09 | 12.03x |
| 2025-07-08 | 12.15x |
| 2025-07-07 | 12.05x |
| 2025-07-03 | 12.14x |
| 2025-07-02 | 12.16x |
| 2025-07-01 | 12.06x |
| 2025-06-30 | 11.80x |
| 2025-06-27 | 11.79x |
| 2025-06-26 | 11.83x |
| 2025-06-25 | 11.86x |
| 2025-06-24 | 11.85x |
| 2025-06-23 | 11.68x |
| 2025-06-20 | 11.65x |
| 2025-06-18 | 11.65x |
| 2025-06-17 | 11.62x |
| 2025-06-16 | 11.89x |
| 2025-06-13 | 11.76x |
| 2025-06-12 | 11.88x |
| 2025-06-11 | 11.86x |
| 2025-06-10 | 11.91x |
| 2025-06-09 | 11.62x |
| 2025-06-06 | 11.53x |
| 2025-06-05 | 11.28x |
| 2025-06-04 | 11.30x |
| 2025-06-03 | 11.04x |
| 2025-06-02 | 10.85x |
| 2025-05-30 | 10.91x |
| 2025-05-29 | 10.95x |
Showing the most recent 260 of 3,292 data points. The chart above shows the full history.
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib